Distinctive Endocrine Profiles and Hyperphagia in Rare Genetic Neurodevelopmental Disorders: Beyond the Prader-Willi Paradigm
Posted inClinical Updates Diabetes & Endocrinology Neurology news

Distinctive Endocrine Profiles and Hyperphagia in Rare Genetic Neurodevelopmental Disorders: Beyond the Prader-Willi Paradigm

This review synthesizes findings from a national multicenter study identifying that hyperghrelinemia is a specific biomarker for Prader-Willi Syndrome, whereas other rare neurodevelopmental disorders exhibit normal ghrelin levels despite severe hyperphagia and significant caregiver burden.
Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency
Posted inClinical Updates Diabetes & Endocrinology news Pediatrics

Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency

This meta-analysis reveals that long-acting growth hormone (LAGH) is associated with a significant increase in BMI SD scores during the first year of treatment and upon switching from daily GH, suggesting a distinct metabolic profile compared to daily regimens.
Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis
Posted inClinical Updates news OB/GYN & Women's Health Orthopedics

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing costs and treatment burden.